We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Eye Implant Stimulates Vision-Restoring Progress

By HospiMedica International staff writers
Posted on 15 Aug 2012
A novel eye implant provides electrical stimulation of the retina that can improve visual perception in blind people with severe to profound retinitis pigmentosa (RP).

The Argus II Retinal Prosthesis System includes an antenna, an electronics case, and an electrode array, and was designed to bypass damaged photoreceptors altogether. More...
The system is based on a video camera set in special glasses that captures a scene. The video is sent to a small patient-worn computer video processing unit (VPU), where it is transformed into excitation instructions sent back to the glasses via a cable. These instructions are then transmitted wirelessly to the antenna in the implant, which passes them to a 60-electrode grid that is surgically implanted and attached to the retina array.

The retina array emits small pulses of electricity that bypass the damaged photoreceptors and stimulate the retina’s remaining cells, which transmit the visual information along the optic nerve to the brain. Patients then learn to interpret these visual patterns, thereby regaining some functional vision. Users of the Argus II bionic eye report that the system helps them perceive rough shapes and track the movement of objects, and that they can slowly read large writing. The result delivers greater independence for patients. The Argus II Retinal Prosthesis System is a product of Second Sight (Sylmar, CA, USA).

“I started to work on retinal implants more than fifteen years ago here in Germany because I knew we could and we should help blind patients suffering from retinitis pigmentosa,” said Prof. Peter Walter, MD, of the Universitäts-Augenklinik RWTH (Aachen, Germany), one of three surgeons in Germany to have implanted Argus II in patients to date. “Today with Argus II, we can finally offer a treatment to patients backed by many years of safety and performance data.”

RP is an inherited, degenerative eye disease that causes severe vision impairment and blindness. A form of retinal dystrophy, RP is caused by abnormalities of the photoreceptors or the retinal pigment epithelium (RPE) of the retina leading to progressive sight loss. Affected individuals may experience defective light to dark or dark to light adaptation, or nyctalopia, as the result of the degeneration of the peripheral visual field (known as tunnel vision). Sometimes, central vision is lost first causing the person to look sidelong at objects.

Related Links:

Second Sight
Universitäts-Augenklinik RWTH



Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Ureteral Dilatation Balloon
Dornier Equinox
LED Surgical Lamp
ACEMST35/57
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.